Yingqi Feng

Dr. Yingqi Feng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
SCShuang Cao
Shuang Cao
YCYongshou Chen
Yongshou Chen
YRYixin Ren
Yixin Ren
YFYingqi Feng
Yingqi Feng
SLSihui Long
Sihui Long
The GLUT is a key regulator of glucose metabolism and is widely expressed on the surface of most cells of the body. GLUT provides a variety of nutrients for the growth, proliferation and differenti...

1 July 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YFYingqi Feng
Yingqi Feng
Zika Virus (ZIKV) is a positive-strand RNA virus that can lead to Guillain-Barré syndrome or encephalitis in some individuals and hence presents a serious public health risk. Since the first outbreak of ZIKV in Brazil in 2015, no effective clinical inhibitors have been developed, making the development of effective ZIKV drugs an urgent issue that needs to be addressed. ZIKV belongs to the Flaviviridae family, and its structure includes three structural proteins, namely, capsular (C), premembrane (prM), and envelope (E) proteins, as well as seven nonstructural proteins, namely, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. To provide a reference for the development of future ZIKV drugs, this paper reviews the structure of the ZIKV based on recent literature reports, analyzes the potential therapeutic targets of various proteins, and proposes feasible drug design strategies. Additionally, this paper reviews and classifies the latest research progress on several protease inhibitors, such as E protein inhibitors, NS2B-NS3 inhibitors, and NS5 inhibitors, so that researchers can quickly understand the current status of development and the interconnections among these inhibitors.

1 September 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
XZXiao-Zheng Zou
Xiao-Zheng Zou
XZXiu-Hua Zhou
Xiu-Hua Zhou
YFYingqi Feng
Yingqi Feng
JHJunfeng Hao
Junfeng Hao
BLBing Liang
Bing Liang
MJMeng-Wei Jia
Meng-Wei Jia

26 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YFYingqi Feng
Yingqi Feng
WWWei Wu
Wei Wu
MLMuzi Li
Muzi Li
In recent years, metal organic frameworks (MOFs) have attracted increasing attention in cancer therapy, because they can enhance the anticancer efficacy of photodynamic therapy (PDT), photothermal therapy (PTT), photoacoustic imaging, and drug delivery. Owing to stable chemical adjustability, MOFs can be used as carriers to provide excellent loading sites and protection for small-molecule drugs. In addition, MOFs can be used to combine with a variety of therapeutic drugs, including chemotherapeutics drugs, photosensitizers, and radiosensitizers, to efficiently deliver drugs to tumor tissue and achieve desired treatment. There is hardly any review regarding the application of MOFs in hepatocellular carcinoma. In this review, the design, structure, and potential applications of MOFs as nanoparticulate systems in the treatment of hepatocellular carcinoma are presented.Systematic Review Registration: website, identifier registration number